Plus a smart paper on why inventing drugs is too expensive and risky to be left to the government
Plus the CBO runs the math on IRA-related costs for 2025 and come up with a real big number
And Blue Shield of California shows that health plans can acquire cheap biosimilar Humira without the help of a PBM
Plus new data on Part D premiums, Newsom torpedoes PBM reform, and a new study on the impact of real-time benefits info
Plus: What's up with Bernie and the PBMs?
Plus an object lesson in how bad data can turn into questionable journalism
The rest of yesterday's hearing: standard-issue, short-shelf-life manufactured drama. Barely worth the popcorn.
Plus what the FTC is asking for in its lawsuit against PBMs
And if you're really tuned into this particular fistfight, there's a 46Brooklyn analysis you need to digest
It's a big day for reports: there's a fantastic look at employer/health plan satisfaction with PBMs, too
And the 340B war of words escalates, but I'm not getting worked up until the legal briefs start flying
And Cigna/Evernorth/Express Scripts decides that the best way to make the FTC PBM report go away is to sue the snot out of the agency
